Older Adults With Cancer Experience Improved Outcomes with Integrated Geriatric Assessment

Article

Researchers showed that integration of a comprehensive geriatric assessment with geriatrician-led management care improved quality of life for older adults with cancer.

Researchers showed that the integration of a comprehensive geriatric assessment with geriatrician-led management care improved quality of life for older adults with cancer undergoing anti-cancer therapy.

The prospective, randomized, parallel-group, open-label INTEGERATE study, presented during a 2020 ASCO Virtual Scientific Program press briefing, is the first randomized study involving both geriatricians and oncologists for the care of older adults with cancer.

“Comprehensive geriatric assessment provides a powerful framework to assess an older person’s health and enables a coordinated, person-centered approach to care,” lead author Wee-Kheng Soo, MBBS, FRACP, a geriatrician and medical oncologist at Eastern Health in Melbourne, Australia, said during a pre-recorded presentation. “Comprehensive geriatric assessment is simply a comprehensive health assessment that focuses on vulnerabilities commonly seen in older people, including functional activities, medical issues, pharmacology, nutrition, memory problems, depression, and social isolation. By recognizing these problems early on, we apply interventions.”

According to an ASCO-issued press release, elderly patients with cancer are only referred to a geriatrician in the later stages of their illness when they experience significant problems with completing everyday tasks. “However, an integrated approach involving comprehensive geriatric assessment and early geriatrician involvement (also known as ‘integrated oncogeriatric care’) can help create a coordinated plan to optimize the older person with cancer.”

In their trial, the researchers included 154 patients aged 70 years or older with cancer who were planned to receive chemotherapy, targeted therapy or immunotherapy. Patients received either geriatrician-led comprehensive geriatric assessment and management (a detailed systematic evaluation identifying medical, psychosocial and functional limitations) integrated with usual care (76 patients) or usual care alone (78 patients).

The primary outcome being measured was health-related quality of life, which consisted of physical, role and social functioning; mobility, burden of illness and future worries. The researchers also evaluated patients’ function, mood, nutrition, health utility, treatment delivery, healthcare utilization and survival.

Assessment was conducted through self-reported questionnaires and a comprehensive assessment by a geriatrician.

Thirteen patients died by week 12 and 130 (92.2% of the remaining patients) completed at least two primary outcome assessments.

The researchers found that the integrated intervention led to improved Elderly Functional Index (ELFI) scores, compared with those who received usual care across all follow-up points.

The intervention group also experienced improvements in functioning, mobility, burden of illness and future worries, which persisted to the end of the study.

Moreover, the researchers saw an average of 1.3 fewer emergency room visits (39%) and 1.2 fewer unplanned hospital admissions per person per year (43%), as well as a reduction in early treatment discontinuations (32.9% versus 53.2%) among those who received intervention versus those who did not. Soo attributed the decline to reduced treatment-related toxicity and pointed out this could potentially be cost saving.

Lastly, the number of overnight stays geriatric patients with cancer had decreased by seven days per person per year (24%).

“We found that oncogeriatric care in older people with cancer about to receive anti-cancer therapy led to significant improvements in health outcomes — at the patient level, quality of life, as well as the system level’s outcomes, such as hospital utilization and treatment delivery,” lead author Wee-Kheng Soo, MBBS, FRACP, a geriatrician and medical oncologist at Eastern Health in Melbourne, Australia, said during a pre-recorded presentation. “These findings suggest that those aged 70 or older with cancer should receive a geriatric clinical assessment to optimize their care and health outcomes.”

The researchers intend to implement the integrated comprehensive geriatric assessment in a large, multicenter implementation study comparing different care models in geriatric oncology and different cancer settings.

“The number of people worldwide over the age of 65 is expected to continue to grow, making the need for more rigorous research to help optimize the quality of care we provide to older patients an urgent priority. This study shows that geriatric assessments lead to clear improvements in quality of life and better care planning for older patients with cancer,” Howard A. Burris III, MD, FACP, FASCO, ASCO president, said in the release.

In an interview with CURE, Dr. Cardinale B. Smith, chief quality officer of cancer services at the Mount Sinai Health System, commented on the study results. “The integration of comprehensive geriatric assessments should be incorporated more widely into the care of older adults with cancer.”

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content